Biotech firm Regenxbio Q2 net loss widens
Biotech firm Regenxbio reported a Q2 net loss of $70.9 million, up from $53.0 million last year, with revenues falling to $21.4 million due to decreased Zolgensma royalties. The company expects a cash runway into early 2027 and is accelerating pivotal trial enrollment for RGX-202. Increased R&D expenses were noted, driven by manufacturing and clinical trials. Analysts maintain a "buy" rating, with a median 12-month price target of $31.50, significantly above its recent closing price of $8.23.
)
Overview
- The clinical-stage biotechnology firm focused on gene therapy posts Q2 net loss of $70.9 mln vs $53.0 mln last year
- Q2 revenues dip to $21.4 mln, mainly due to lower Zolgensma royalties
Outlook
- Regenxbio anticipates cash runway into early 2027
Result Drivers
- RGX-202 PROGRESS - Accelerated pivotal trial enrollment for Duchenne muscular dystrophy, expected to complete by October 2025
- ZOLGENSMA ROYALTY DECLINE - Revenue decrease mainly attributed to lower Zolgensma royalties, partially offset by Nippon Shinyaku partnership service revenues
- INCREASED R&D EXPENSES - Higher costs due to manufacturing and clinical trials for sura-vec and RGX-202
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q2 $18.46
License mln
&
Royalty
Revenue
Q2 Net -$70.87
Income mln
Q2 $84.64
Operatin mln
g
Expenses
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 11 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Regenxbio Inc is $31.50, about 73.9% above its August 6 closing price of $8.23
Press Release: (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
